Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer

5 Aug 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Extracellular vesicles in disease
Share to Immunotherapy and Immune Responses

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40762902
DOI: 10.1007/s13346-025-01920-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancerPMID 40762902Read ↗

Exosomes as Therapeutic Vehicles for CancerSemantic proximity Read ↗

Engineered T cells for anti-cancer therapySemantic proximity Read ↗

Engineered T cells for cancer therapySemantic proximity Read ↗

Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeuticsSemantic proximity Read ↗

Enhancing Breast Cancer Therapy: Nanocarrier-Based Targeted Drug DeliverySemantic proximity Read ↗

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical modelsSemantic proximity Read ↗

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast CancerSemantic proximity Read ↗

Genetically Engineered Cytomembrane Nanovaccines for Cancer ImmunotherapySemantic proximity Read ↗

Genetically engineered T cells for cancer immunotherapySemantic proximity Read ↗

In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cellsSemantic proximity Read ↗

Red Blood Cell-derived Extracellular Vesicles enable Cisplatin and Cetuximab combined Therapy against Triple-Negative Breast CancerSemantic proximity Read ↗

Genetically engineered T cells for the treatment of cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.